跳至主要内容
临床试验/IRCT20220809055645N1
IRCT20220809055645N1招募中2 期

Effectiveness and safety of Apixaban versus Warfarin in patients with left ventricular thrombus following acute myocardial infarction: A randomized clinical trial

Rasht University of Medical Sciences0 个研究点目标入组 104 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
104

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • All patients with left ventricular thrombosis within two weeks after acute myocardial infarction, if there is no contraindication to the use of anticoagulants

排除标准

  • History of active bleeding,
  • History of coagulation disorders,
  • Contraindications to Apixaban or warfarin (For example, in patients with ESRD),
  • Drug sensitivity to Apixaban or warfarin,
  • Moderate to severe mitral stenosis,
  • Mechanical valve disease,
  • GFR less than 25,
  • If INR is not within the control-normal range, i.e. 2 to 3,
  • Consumption of drugs which interfere with Apixaban (such as amiodarone, antifungal drugs, anti-AIDS drugs, etc.)

研究者

发起方
Rasht University of Medical Sciences

相似试验